Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Granella

Showing results (31-40 of 112) with videos related to

Pageof 12
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
The Journal of Headache and Pain|May 15, 2012
Italian guidelines for primary headaches: 2012 revised versionPaola Sarchielli, Franco Granella, Maria Pia Prudenzano, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 15, 2020
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosisClara Grazia Chisari, Luigi Maria Grimaldi, Giuseppe Salemi, et al.
Current Medical Research and Opinion|March 13, 2018
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistenceDiana Ferraro, Valentina Camera, Eleonora Baldi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 25, 2017
Definitive childlessness in women with multiple sclerosis: a multicenter studyDiana Ferraro, Anna Maria Simone, Giorgia Adani, et al.
Plos One|June 28, 2016
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective StudyEmanuele D'Amico, Carmela Leone, Giusi Graziano, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 15, 2025
Multiple sclerosis from onset to secondary progression: a 30-year Italian register studyAurora Zanghì, Massimiliano Copetti, Carlo Avolio, et al.
Pageof 12

Showing results (31-40 of 112) with videos related to

Sort By:
Pageof 12
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
The Journal of Headache and Pain|May 15, 2012
Italian guidelines for primary headaches: 2012 revised versionPaola Sarchielli, Franco Granella, Maria Pia Prudenzano, et al.
Multiple Sclerosis and Related Disorders|February 6, 2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activityTim Spelman, Dana Horakova, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 15, 2020
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosisClara Grazia Chisari, Luigi Maria Grimaldi, Giuseppe Salemi, et al.
Current Medical Research and Opinion|March 13, 2018
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistenceDiana Ferraro, Valentina Camera, Eleonora Baldi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 25, 2017
Definitive childlessness in women with multiple sclerosis: a multicenter studyDiana Ferraro, Anna Maria Simone, Giorgia Adani, et al.
Plos One|June 28, 2016
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective StudyEmanuele D'Amico, Carmela Leone, Giusi Graziano, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 15, 2025
Multiple sclerosis from onset to secondary progression: a 30-year Italian register studyAurora Zanghì, Massimiliano Copetti, Carlo Avolio, et al.
Pageof 12